

---

## ERRATA

---

The November 20, 2008, article by Spearman et al entitled, “Clinically Applicable Models to Characterize *BRCA1* and *BRCA2* Variants of Uncertain Significance” (J Clin Oncol 26:5393-5400, 2008) contained an error. The study support received by Fergus J. Couch was inadvertently omitted, and should have been acknowledged as follows:

Supported by the National Institutes of Health, National Cancer Institute, Bay Area Breast Spore Career Development Award No. P50 CA582017 (A.E.T.), Mayers Summer fellowships (A.D.S.), internal funds from the Ohio State University Comprehensive Cancer Center (A.E.T.), Mayo Clinic Breast Grant No. SPORE P50 CA116201 (F.J.C.), the National Institutes of Health Grant No. R01 CA116167 (F.J.C.), and the American Cancer Society Grant No. RSG-04-220-01-CCE (F.J.C.).

DOI: 10.1200/JCO.2009.23.1332

---

The January 1, 2009, article by Olivotto et al entitled, “Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy” (J Clin Oncol 27:16-23, 2009) contained errors.

In parts B, C and D of Figures 2 and 3, the comparison curves (yellow lines) were labeled as 8-12 weeks, whereas they should have been labeled as > 12-16 weeks in part B, > 16-20 weeks in part C, and > 20-42 weeks in part D.

In the legend for Figure 3, the *P* values were incorrect and should have been *P* = .723 for part A, *P* = .184 for part B, *P* = .997 for part C, *P* = .007 for part D, as given in the figure.

DOI: 10.1200/JCO.2009.23.1365

---

The March 10, 2009, article by Reck et al, entitled, “Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL” (J Clin Oncol 27:1227-1234, 2009) contained errors.

In Table 3, the footnote for neutropenia was given as:

\*Febrile neutropenia occurred in one (0.3%), two (0.6%), and two (0.6%) patients in the placebo, low-dose bevacizumab, and high-dose bevacizumab arms, respectively.

Whereas it should have been:

\*Febrile neutropenia occurred in four (1%), five (2%), and seven (2%) patients in the placebo, low-dose bevacizumab, and high-dose bevacizumab arms, respectively.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.23.1373

---